EU nod for Sanofi’s next-gen rabies vaccine for all age groups
Sanofi's VaxRabeo, a new rabies vaccine, received EU approval for all age groups. It uses advanced technology, has a longer shelf life, and improved stability. The WHO reports rabies kills 59,000 annually, with 29 million receiving post-exposure vaccines yearly. Sanofi's CEO highlighted the vaccine's importance in preventing a fatal but preventable disease.
How this was made
The 30-second read
Why it matters
The approval expands Sanofi's vaccine portfolio, offering longer shelf life and improved thermostability, which could capture market share from existing rabies vaccines.
Market read
First EU approval of a novel rabies vaccine may positively influence Sanofi's stock and the broader vaccine sector.
What to watch
Potential reimbursement negotiations and manufacturing scale‑up risks could temper the impact.
Background
Sanofi announced EU marketing authorisation for VaxRabeo, a next‑generation rabies vaccine using Vero‑cell technology, covering all age groups for both pre‑ and post‑exposure prophylaxis.
Ticker impact
EU Commission approved Sanofi's next‑gen rabies vaccine VaxRabeo, a first marketing authorisation for the product.
likely upward pressure as market prices in the new product opportunity
First‑time EU marketing authorisation for a novel rabies vaccine adds a new revenue stream and strengthens Sanofi's immunisation franchise.
Market effects
enhances the global vaccine and biologics sector with a new advanced‑cell technology product
EU markets may see modest uplift in pharma stocks following the approval
adds competitive pressure on other rabies vaccine makers worldwide
Counterpoint
The market may have already priced in Sanofi's pipeline strength, limiting upside from this single approval.
Key entities
- CompanySanofi
Global pharmaceutical company receiving EU approval for VaxRabeo.
- RegulatorEuropean Commission
Authority granting the marketing authorisation.



